Eflornithine is a cost‐effective alternative to melarsoprol for the treatment of second‐stage human West African trypanosomiasis in Caxito, Angola

Abstract

Eflornithine saves more lives than melarsoprol, but melarsoprol is slightly more cost-effective. Switching from melarsoprol to eflornithine can be considered as a cost-effective option according to the WHO choice criteria.